HZ/su vaccine

BIOLOGICAL4 trials

Sponsors

University of Colorado, Denver, GlaxoSmithKline, Pfizer

Conditions

Herpes ZosterRespiratory Syncytial Virus (RSV)Respiratory Syncytial Virus InfectionsRespiratory Syncytial VirusesShingles

Phase 1

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

CompletedNCT02114333

University of Colorado, DenverHerpes Zoster, Shingles

Start: 2014-05-31End: 2020-05-31Updated: 2020-07-08

Phase 3

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Active, not recruitingNCT05371080

GlaxoSmithKlineHerpes Zoster

Start: 2022-08-10End: 2027-08-23Target: 3038Updated: 2024-01-18

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

CompletedNCT05966090

GlaxoSmithKlineRespiratory Syncytial Viruses, Respiratory Syncytial Virus Infections

Start: 2023-07-28End: 2024-07-29Updated: 2025-04-01

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

CompletedNCT06890416

PfizerRespiratory Syncytial Virus (RSV)

Start: 2025-04-04End: 2025-09-30Updated: 2025-11-06

Related Papers

Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications.

2025-05-09

Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence

The Journal of Infectious Diseases2021-11-2518 citations

Comparative Immune Responses to Licensed Herpes Zoster Vaccines

The Journal of Infectious Diseases2018-07-1443 citations